Tenax Therapeutics Inc - Asset Resilience Ratio
Tenax Therapeutics Inc (TENX) has an Asset Resilience Ratio of 0.00% as of December 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2021)
This chart shows how Tenax Therapeutics Inc's Asset Resilience Ratio has changed over time. Check Tenax Therapeutics Inc (TENX) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Tenax Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Tenax Therapeutics Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Tenax Therapeutics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Tenax Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Tenax Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Tenax Therapeutics Inc (2011–2021)
The table below shows the annual Asset Resilience Ratio data for Tenax Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 0.00% | $0.00 | $5.99 Million | -- |
| 2020-12-31 | 6.74% | $462.69K | $6.87 Million | -1.02pp |
| 2019-12-31 | 7.76% | $493.88K | $6.37 Million | +4.05pp |
| 2018-12-31 | 3.71% | $494.63K | $13.34 Million | -58.19pp |
| 2017-12-31 | 61.90% | $6.12 Million | $9.89 Million | +47.83pp |
| 2016-12-31 | 14.07% | $3.28 Million | $23.34 Million | -8.57pp |
| 2015-12-31 | 22.65% | $16.53 Million | $72.99 Million | +12.80pp |
| 2014-12-31 | 9.85% | $9.20 Million | $93.43 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $93.43 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $33.94 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $5.89 Million | -- |
About Tenax Therapeutics Inc
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imat… Read more